Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Narrowing Part D Protected Classes Won’t Be Proposed Again – Tavenner

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS Administrator Tavenner provides public assurances that the agency will not reintroduce a proposal to remove antidepressants, antipsychotics and immunosuppressants from protected status in the Medicare Part D program.

You may also be interested in...



CMS’ Likely Reversal Of Threat To Part D Protected Classes Doesn’t Mean Other Reforms Aren’t Coming

Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.

Under Pressure, CMS Backs Off New Part D Protected Class Management

Decision in final rule marks a setback in the Trump Administration’s game plan for lowering drug prices. But CMS proceeds with codifying previous guidance allowing step therapy for Part B drugs in Medicare Advantage.

CMS Part D Protected Class Restrictions Drawing Bipartisan Concerns In Congress

Congressional objections to proposal join opposition by patient and physician groups.

Related Content

Topics

UsernamePublicRestriction

Register

PS077714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel